Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | GPR3 | P46089 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL19915225 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL25285896 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL20570425 | 0.92 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL25292878 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL25287606 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL25301943 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL23430060 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL25255863 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL25292546 | 0.92 | GPR3 (0.48) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL5595336 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108912127-B | Benzo [ b, e ] azepine compound based on isatin skeleton and preparation method thereof | 青岛农业大学 | 2019-12-10 | — | — | CN | claimed |
| US-12628547-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260090262-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4701391-A2 | HETEROLEPTIC IRIDIUM COMPLEX | Universal Display Corporation (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12550604-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| EP-3643721-B1 | HETEROLEPTIC IRIDIUM COMPLEX | UNIVERSAL DISPLAY CORP (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12527214-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250366362-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250359473-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERAL DISPLAY CORPORATION (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250338370-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2025-10-30 | — | — | US | disclosed |
| US-20090124805-A1 | METHOD FOR SYNTHESIS OF IRIDUIM (III) COMPLEXES WITH STERICALLY DEMANDING LIGANDS | UNIVERSAL DISPLAY CORPORATION | 2009-05-14 | — | — | US | disclosed |
| US-20090108737-A1 | LIGHT-EMITTING ORGANOMETALLIC COMPLEXES | UNIVERSAL DISPLAY CORPORATION | 2009-04-30 | — | — | US | disclosed |
| EP-2043611-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | Nucryst Pharmaceuticals Corp. (CA) | 2009-04-08 | — | — | EP | disclosed |
| US-20080220265-A1 | Cross-linkable Iridium Complexes and Organic Light-Emitting Devices Using the Same | UNIVERSAL DISPLAY CORPORATION (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008073440-A2 | CROSS-LINKABLE IRIDIUM COMPLEXES AND ORGANIC LIGHT-EMITTING DEVICES USING THE SAME | UNIVERSAL DISPLAY CORPORATION (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080050452-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-02-28 | — | — | US | disclosed |
| US-20080044491-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-02-21 | — | — | US | disclosed |
| US-20080014247-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-01-17 | — | — | US | disclosed |
| US-20080014278-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-01-17 | — | — | US | disclosed |
| WO-2008005705-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS CORP. (CA) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250366362-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, ICOSLG | CA1 4823/4885CA2 4391/4885CA7 4249/4885 |
| US-20090108737-A1 | LIGHT-EMITTING ORGANOMETALLIC COMPLEXES | CRY1, LAGE3, CRY2 | CA1 4244/4885CA2 3000/4885CA7 3135/4885 |
| US-20250338370-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | CA1 4710/4885CA2 3651/4885CA7 4290/4885 |
| US-20260090262-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | TLL1, TLL2, LAS1L | CA1 2017/4885CA2 1802/4885CA7 3862/4885 |
| US-20080220265-A1 | Cross-linkable Iridium Complexes and Organic Light-Emitting Devices Using the Same | MTCL3, LIG4, L1CAM | CA1 2670/4885CA2 3128/4885CA7 2441/4885 |
| US-20250359473-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, OSBP | CA1 4852/4885CA2 4659/4885CA7 4623/4885 |
| US-20090124805-A1 | METHOD FOR SYNTHESIS OF IRIDUIM (III) COMPLEXES WITH STERICALLY DEMANDING LIGANDS | PAICS, ITPA, MPI | CA1 4472/4885CA2 4422/4885CA7 3478/4885 |
| US-12628547-B2 | Organic electroluminescent materials and devices | ZYX, PYM1, MSL1 | CA1 1230/4885CA2 1914/4885CA7 2491/4885 |
| US-12550604-B2 | Organic electroluminescent materials and devices | ROS1, DNMT3A, PRDM9 | CA1 3145/4885CA2 3251/4885CA7 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.